We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Test Diagnoses Bacterial Meningitis Quickly and Accurately

By LabMedica International staff writers
Posted on 30 Apr 2025
Print article
Image: CRP protein in cerebrospinal fluid was found to be a very reliable indicator of bacterial meningitis (Photo courtesy of 123RF)
Image: CRP protein in cerebrospinal fluid was found to be a very reliable indicator of bacterial meningitis (Photo courtesy of 123RF)

Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical. However, distinguishing bacterial meningitis from other similar conditions is often challenging for healthcare providers. Currently, it can take a considerable amount of time to diagnose meningitis, which delays the initiation of appropriate treatment. Until now, there have been no reliable diagnostic tests available that could quickly differentiate bacterial meningitis from other conditions. Researchers have now developed a new diagnostic test capable of quickly and accurately diagnosing bacterial meningitis by measuring the CRP protein in cerebrospinal fluid, a protein commonly tested in blood to detect bacterial infections.

Researchers at Amsterdam UMC (Amsterdam, Netherlands) found that the CRP protein in cerebrospinal fluid is a highly reliable indicator of bacterial meningitis. While CRP is often tested in blood to detect bacterial infections, its value in cerebrospinal fluid had not been extensively studied until now. After successful laboratory tests, the researchers demonstrated that the device used to measure CRP in blood is also sensitive enough to measure CRP in cerebrospinal fluid. Since June 2024, this new test has been incorporated into daily practice at Amsterdam UMC. In their latest, published in The Lancet Regional Health Europe, the researchers described how the test was introduced and assessed its effectiveness in a clinical setting.

The results showed that all patients diagnosed with bacterial meningitis had elevated CRP levels in their cerebrospinal fluid, whereas only a few patients without bacterial meningitis showed similar elevations. The test was also proven to be reliable in additional studies conducted with children and patients in Denmark. It is expected that more hospitals will begin to adopt this test, as it can be performed in laboratories with existing equipment. The cost of the test ranges from three to five euros, offering an affordable and accessible solution for diagnosing and treating bacterial meningitis more quickly.

"Any laboratory in which CRP is measured in blood can introduce this test for cerebrospinal fluid tomorrow. We could not have predicted in advance that a new diagnostic test would be used in patients within a year of its discovery," said last author and Amsterdam UMC neurologist, Matthijs Brouwer.

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
Benchtop Cooler
PCR-Cooler & PCR-Rack

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.